The 2.27% mean decrease in BMD of lumbar spine from baseline to week 12 observed in the 40-mg group in our study is in line with the 2.7% mean decrease following 3 months of treatment with 3.75 mg of the GnRH agonist, leuprolide acetate, in another uterine leiomyoma study [22]. This evidence concerns the gene GNRH1 and Uterine leiomyoma.